CRL — CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
—
NYSE ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1100682 ·
Last close
$295.01
Market Cap
$14.21B
52W High
$303.31
52W Low
$146.20
ADV30
944,656
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,004,078,000 | 363,374,000 | 119,888,000 | -1,482,000 | 7,532,145,000 | 192,025,000 | 4,643,618,000 |
| Mar 2026 | 995,830,000 | 294,664,000 | 119,897,000 | -14,843,000 | 7,730,308,000 | 191,830,000 | 4,741,995,000 |
| Dec 2025 | 994,227,000 | 309,684,000 | 92,534,000 | -276,555,000 | 7,135,422,000 | 213,770,000 | 3,924,228,000 |
| Sep 2025 | 1,004,852,000 | 338,792,000 | 133,799,000 | 54,422,000 | 7,513,812,000 | 207,097,000 | 4,062,995,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$607,026,000
Investing CF
$-571,687,000
Financing CF
$-83,677,000
CapEx
$-215,736,000
Dividends Paid
—
Buybacks
$-215,826,000
EPS Diluted TTM
$-3.76
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$1,372,295,000
Inventory
$346,260,000
Receivables
$711,755,000
ST Investments
—
EBIT TTM
$-77,411,000
Pretax Income TTM
$-183,671,000
Interest Exp TTM
$106,260,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,998,987,008
EBITDA
$849,118,016
Free Cash Flow
$468,856,000
Enterprise Value
$16,175,003,648
Total Cash
$192,024,992
Total Debt
$3,034,319,104
Shares Out
48,167,730
Trailing EPS
$-4.81
Book Value
$59.50
ROE
-7.5%
ROA
4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,015,382,000 | 401,136,000 | -144,338,000 | 7,135,422,000 | 3,924,228,000 | 3,164,630,000 | 737,646,000 |
| Dec 2024 | 4,049,989,000 | 442,347,000 | 10,297,000 | 7,528,345,000 | 4,020,267,000 | 3,461,503,000 | 734,577,000 |
| Dec 2023 | 4,129,409,000 | 617,261,000 | 474,624,000 | 8,195,001,000 | 4,536,003,000 | 3,596,882,000 | 683,898,000 |
| Dec 2022 | 3,976,060,000 | 650,975,000 | 486,226,000 | 7,602,770,000 | 4,579,265,000 | 2,976,293,000 | 619,640,000 |
TTM Snapshot
Revenues TTM
$4,009,711,000
NetIncome TTM
$278,988,000
OpCashFlow TTM
$0
Assets (Latest)
$7,135,422,000
Forward EPS
$12.69
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $210.00 · spot: $295.01 · call volume: 619 · put volume: 145
Expected Move to 2026-10-16:
±$25.30
(8.58%) —
implied range
$269.71 –
$320.31
· ATM straddle on $300.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ICLR | ICON PLC | $13.12B | $169.99 | — |
| MEDP | Medpace Holdings, Inc. | $17.42B | $624.18 | — |
| INCY | INCYTE CORP | $24.60B | $121.35 | — |
| LNTH | Lantheus Holdings, Inc. | $6.50B | $99.53 | — |
| IDXX | IDEXX LABORATORIES INC /DE | $41.14B | $522.19 | — |
News headlines (Yahoo Finance, 1h cache)
Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson La
2026-09-30 13:28 · Yahoo
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery
2026-09-29 16:11 · Yahoo
Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cam
2026-09-29 15:52 · Yahoo
Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaro
2026-09-29 15:51 · Yahoo
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
2026-09-29 11:33 · Yahoo
Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, T
2026-09-29 08:07 · Yahoo
Is Charles River Laboratories Stock Outperforming the S&P 500?
2026-09-27 20:55 · Yahoo
Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch
2026-09-25 06:09 · Yahoo
Why Charles River Laboratories (CRL) Stock Is Up Today
2026-09-24 23:04 · Yahoo
Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec
2026-09-24 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.